• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Journal articles
    • View Item
    • Home
    • Griffith Research Online
    • Journal articles
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Real-world retention rates with a long-acting buprenorphine depot in opioid-dependent patients attending private clinics in Australia

    Author(s)
    MacDonald, Tim
    Griffith University Author(s)
    MacDonald, Tim S.
    Year published
    2021
    Metadata
    Show full item record
    Abstract
    Background. Two depot formulations of buprenorphine are publicly funded in Australia for the maintenance treatment of opioid use disorder within a framework of medical, social and psychological treatment. We report retention rates and patient characteristics at three private clinics in Australia where monthly depot buprenorphine injection was available through an early access scheme from January 2019 to February 2020. Methods. Fifty-three patients receiving transmucosal buprenorphine (mean dose 16 mg daily [range 6–32 mg]) transferred to monthly buprenorphine depot. The overall retention rate, and retention rates based on ...
    View more >
    Background. Two depot formulations of buprenorphine are publicly funded in Australia for the maintenance treatment of opioid use disorder within a framework of medical, social and psychological treatment. We report retention rates and patient characteristics at three private clinics in Australia where monthly depot buprenorphine injection was available through an early access scheme from January 2019 to February 2020. Methods. Fifty-three patients receiving transmucosal buprenorphine (mean dose 16 mg daily [range 6–32 mg]) transferred to monthly buprenorphine depot. The overall retention rate, and retention rates based on discontinuation defined as a 2- or 4-week treatment delays, were calculated. Results. Six patients who had planned managed discontinuations from treatment were censored. Four uncensored patients (i.e. expected to continue treatment) missed one depot injection, one missed two, and three discontinued. Kaplan–Meier analysis predicted 67–93% retention at 1 year, depending on the definition of discontinuation. Median time between treatments was 30 days with all definitions. Median retention was not reached in any definition. The patient population (70% male; mean age 39 years; 60% prior heroin users) was consistent with the 2020 National Opioid Pharmacotherapy Statistics Annual Data profile. Most patients were maintained on 100 mg monthly depot; this was not predicted by prior transmucosal buprenorphine dose, age or gender identity. Treatment with this monthly buprenorphine depot supported retention for most patients while allowing flexibility in dosage and dose interval. The small sample and observational design limit predictive power. Conclusions. Monthly buprenorphine depot promotes long-term treatment for patients in real-world settings.
    View less >
    Journal Title
    Heroin Addiction And Related Clinical Problems
    Publisher URI
    https://www.heroinaddictionrelatedclinicalproblems.org/index.php
    Note
    This publication has been entered in Griffith Research Online as an advanced online version.
    Subject
    Psychiatry (incl. psychotherapy)
    Pharmaceutical delivery technologies
    Pharmacology and pharmaceutical sciences
    Publication URI
    http://hdl.handle.net/10072/408944
    Collection
    • Journal articles

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander